Wednesday, October 29, 2025 10/29/2025

Component A; Opioid Use Disorder in Pregnancy and Neonatal Opioid Withdrawal Syndrome Longitudinal Surveillance Project

Award Number: NU01DD000016
ORGANIZATION: NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES (NCBDDD)
OPDIV: CDC
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: HEALTH SERVICES
PERIOD OF PERFORMANCE START DATE: 09/30/2023
PERIOD OF PERFORMANCE END DATE: 09/29/2027

Group Awards By:

View Award Description

Component A; Opioid Use Disorder in Pregnancy and Neonatal Opioid Withdrawal Syndrome Longitudinal Surveillance Project - Opioid use disorder (OUD) among pregnant individuals is a key public health crisis in need for improved longitudinal surveillance efforts. There has been more than a four-fold increase in the number of deliveries impacted by (OUD) in pregnancy and a sevenfold increase in the rate of neonatal opioid withdrawal syndrome (NOWS) between 2000 to 2016 in the United States (U.S.). The standard of care for pregnant individuals with OUD is to receive medication for opioid use disorder (MOUD) with associated improved pregnancy and perinatal outcomes. In recent years, new treatment modalities for OUD have emerged with limited data on pregnancy, neonatal, or childhood outcomes. In addition, polysubstance use impacts many of individuals with OUD, including continued non-prescribed drug use and psychiatric medication use for co-occurring mental health conditions. The impact of these polysubstance exposures on pregnancy and neonatal outcomes is unclear. Lastly, NOWS is a highly variable condition, impacted by the changes in hospital treatment strategies and numerous clinical factors including type of MOUD and polypharmacy exposures. Rigorous data on the long-term outcomes of opioid-exposed infants is limited, with concerns about behavioral issues, school challenges, attentional difficulties, and risk for developmental challenges. There is a need for detailed patient-level electronic health record (EHR) data from a large cohort to be able to account for all prenatal substance exposures and infant variables that can influence the long-term outcomes of these children through a comprehensive longitudinal surveillance program. Our team at Boston Medical Center (BMC), a Component A institution, is comprised of nationally recognized experts in the field of OUD in pregnancy and NOWS with a decade-long track record of clinical innovation, research excellence, and dissemination of best practices across the country. We hope to continue to partner with the CDC on this surveillance project, assisting with advancing the science and dissemination of best practice data. With our exposures and outcomes of interest being (1) opioid-exposure in pregnancy, (2) polysubstance exposure in pregnancy, and (3) NOWS, we aim to achieve the following outcomes over the 1-year performance period: (1) Improve surveillance data collection; (2) Increase access and availability of EHR data; (3) Improve timely reporting of key exposures and outcomes; (4) Improve surveillance system data that can be leveraged for emerging threats; (5) Increase awareness by CDC of the data and how they are shared; (6) Increase implementation of prevention activities and dissemination; (7) Expand and strengthen our collaborative network; and (8) Improve data structure and increase interoperability. We will accomplish this goals by implementing key strategies and activities including: (1) Coordinating with the CDC and other recipients to identify opportunities for collaboration; (2) Engaging in data modernization initiatives; (3) Establishing collaborations with internal and external partners to strengthen data collection and translation of the data; (4) Monitoring and evaluating data for completeness, accuracy, and timeliness; (5) Using the data for prevention activities; and (6) Abstract and extracting EHR data from pregnant person-infant dyads from pregnancy through 6 years of age for surveillance and submitting this data to the CDC. The end result will be the establishment of a robust longitudinal surveillance database to assist us with the establishment of best practice data that can then be disseminated across the U.S. to improve the care of pregnant individuals with OUD, polysubstance exposure, and infants with NOWS.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $461,000 )
2025	2025	BOSTON MEDICAL CENTER CORPORATION	1 BOSTON MEDICAL CTR PL	BOSTON	MA	02118	SUFFOLK	USA	Birth Defects and Developmental Disabilities - Prevention and Surveillance	00	3	9/17/2025	NON-COMPETING CONTINUATION	$461,000
2025	2024	BOSTON MEDICAL CENTER CORPORATION	1 BOSTON MEDICAL CTR PL	BOSTON	MA	02118	SUFFOLK	USA	Birth Defects and Developmental Disabilities - Prevention and Surveillance	01	2	12/26/2024	ADMINISTRATIVE SUPPLEMENT ( + OR - ) (DISCRETIONARY OR BLOCK AWARDS)	$0
2025	2024	BOSTON MEDICAL CENTER CORPORATION	1 BOSTON MEDICAL CTR PL	BOSTON	MA	02118	SUFFOLK	USA	Birth Defects and Developmental Disabilities - Prevention and Surveillance	00	3	9/17/2025	NON-COMPETING CONTINUATION	$0
2025	2023	BOSTON MEDICAL CENTER CORPORATION	1 BOSTON MEDICAL CTR PL	BOSTON	MA	02118	SUFFOLK	USA	Birth Defects and Developmental Disabilities - Prevention and Surveillance	00	3	9/17/2025	NON-COMPETING CONTINUATION	$0
2025	2023	BOSTON MEDICAL CENTER CORPORATION	1 BOSTON MEDICAL CTR PL	BOSTON	MA	02118	SUFFOLK	USA	Birth Defects and Developmental Disabilities - Prevention and Surveillance	01	2	12/26/2024	ADMINISTRATIVE SUPPLEMENT ( + OR - ) (DISCRETIONARY OR BLOCK AWARDS)	$0
														Subtotal = $461,000

Issue Date FY: 2024 ( Subtotal = $461,410 )
2024	2024	BOSTON MEDICAL CENTER CORPORATION	1 BOSTON MEDICAL CTR PL	BOSTON	MA	02118	SUFFOLK	USA	Birth Defects and Developmental Disabilities - Prevention and Surveillance	00	2	8/13/2024	NON-COMPETING CONTINUATION	$461,410
2024	2023	BOSTON MEDICAL CENTER CORPORATION	1 BOSTON MEDICAL CTR PL	BOSTON	MA	02118	SUFFOLK	USA	Birth Defects and Developmental Disabilities - Prevention and Surveillance	01	1	11/28/2023	ADMINISTRATIVE SUPPLEMENT ( + OR - ) (DISCRETIONARY OR BLOCK AWARDS)	$0
2024	2023	BOSTON MEDICAL CENTER CORPORATION	1 BOSTON MEDICAL CTR PL	BOSTON	MA	02118	SUFFOLK	USA	Birth Defects and Developmental Disabilities - Prevention and Surveillance	00	2	8/13/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $461,410

Issue Date FY: 2023 ( Subtotal = $480,635 )
2023	2023	BOSTON MEDICAL CENTER CORPORATION	1 BOSTON MEDICAL CTR PL	BOSTON	MA	02118	SUFFOLK	USA	Birth Defects and Developmental Disabilities - Prevention and Surveillance	00	1	8/31/2023	NEW	$480,635
														Subtotal = $480,635

Grand Total All Awards = $1,403,045

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Component A; Opioid Use Disorder in Pregnancy and Neonatal Opioid Withdrawal Syndrome Longitudinal Surveillance Project

Award Number: NU01DD000016

ORGANIZATION: NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES (NCBDDD)

OPDIV: CDC

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: HEALTH SERVICES

PERIOD OF PERFORMANCE START DATE: 09/30/2023

PERIOD OF PERFORMANCE END DATE: 09/29/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer